NLRP3 and Parkinson disease: Human MSCs negatively regulate lipopolysaccharide (LPS)-induced NLRP3 inflammasome activation in macrophages to decrease in vitro (37, 38), while the effects of systemic MSC administration on the NLRP3 inflammasome have not been described for PD.